高滴度恢复期血浆早期治疗住院COVID-19患者:DAWn-plasma试验
DAWn-plasma为前瞻性多中心随机试验,将住院COVID-19成人患者按2:1随机分配至4单位开放标签恢复期血浆联合标准治疗组或单纯标准治疗组,首选中和抗体滴度(NT50)≥1/320的供者血浆。第15天存活且无需机械通气的比例两组无差异(83.74% vs 84.05%,OR 0.99,95%CI 0.59-1.66,p=0.9772),未显著改善临床状态或降低死亡率。
要点
- 高滴度恢复期血浆未提高第15天存活且无机械通气比例。
- 干预未改变抗体滴度的自然演变过程。
- 输血相关副作用见于320例中19例(5.94%)。
核心结论
- 住院COVID-19患者早期输注4单位高中和抗体滴度恢复期血浆,未显著改善临床状态或降低死亡率。
研究设计与样本
- 前瞻性多中心随机对照试验DAWn-plasma,320例随机至恢复期血浆组、163例至对照组,按2:1分配。
- 纳入住院COVID-19成人患者,干预组接受4单位开放标签恢复期血浆联合标准治疗,对照组仅标准治疗。
主要发现
- 第15天存活且无机械通气的比例:血浆组83.74%(n=267),对照组84.05%(n=137),OR 0.99,95%CI 0.59-1.66,p=0.9772。
- 中位输注血浆体积884 mL(IQR 806-906),80.68%的血浆单位来自NT50≥1/320的供者。
- 从症状出现至随机化的中位时间为7天。
- 干预未改变抗体滴度的自然演变过程。
- 严重或重度不良事件数量两组相似,干预组320例中19例(5.94%)报告输血相关副作用。
关键数值与推荐
- 供者血浆中和抗体滴度(NT50)≥1/320为研究首选产品。
- 随机化按2:1分配至血浆组与对照组。
临床怎么用
- 住院COVID-19患者早期使用高滴度恢复期血浆未显示临床获益,不支持以改善临床状态或降低死亡率为目的常规使用。
局限性
- 原文摘要未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness. METHODS: In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT50)) ≥1/320 was the product of choice for the study. RESULTS: Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806-906) mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59-1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%). CONCLUSIONS: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality.
引用
- Devos T, Van Thillo Q, Compernolle V, et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J. 2022. PMID: 34446469. doi:10.1183/13993003.01724-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。